```html

Fatty Liver (Hepatic Steatosis)

What is Fatty Liver?

Fatty liver, medically known as hepatic steatosis, occurs when excess fat builds up in the liver cells. A small amount of fat (≤5% of liver weight) is normal, but when fat exceeds this threshold the organ can become inflamed, scarred, and eventually fail. Fatty liver disease exists on a spectrum:

• Non‑alcoholic fatty liver disease (NAFLD) – fat accumulation not caused by significant alcohol intake.
• Alcoholic fatty liver disease (AFLD) – caused by excessive alcohol consumption.
• Non‑alcoholic steatohepatitis (NASH) – a more aggressive form of NAFLD that includes inflammation and liver cell injury.
• Cirrhosis – the end‑stage of chronic liver damage when scar tissue replaces healthy tissue.

The condition is often silent, especially in early stages, which is why routine screening in at‑risk individuals is essential. According to the CDC and Mayo Clinic, NAFLD affects up to 25‑30% of adults in the United States, making it the most common chronic liver disease worldwide.

Common Causes

Fatty liver can develop for many reasons. Below are the most frequent contributors (both metabolic and environmental):

• Obesity – especially central (visceral) obesity.
• Insulin resistance / Type 2 diabetes – high insulin levels promote fat storage in the liver.
• Excessive alcohol use – typically >14 drinks/week for men or >7 drinks/week for women.
• High‑calorie, high‑sugar diets – fructose‑rich beverages, fast food, and processed snacks.
• Metabolic syndrome – a cluster of hypertension, dyslipidemia, hyperglycemia, and abdominal obesity.
• Rapid weight loss or malnutrition – e.g., after bariatric surgery or severe illness.
• Medications – glucocorticoids, amiodarone, methotrexate, tamoxifen, and some antiretrovirals.
• Genetic / inherited disorders – such as familial hyperlipidemia, Wilson disease, or alpha‑1 antitrypsin deficiency.
• Chronic viral hepatitis – hepatitis C can coexist with steatosis.
• Pregnancy‑related cholestasis – rare but can temporarily increase liver fat.

Associated Symptoms

Most people with early‑stage fatty liver have no symptoms. When the disease progresses, patients may notice:

• Persistent fatigue or weakness.
• Right‑upper‑quadrant abdominal discomfort or fullness.
• Unexplained weight loss or loss of appetite.
• Occasional nausea or mild indigestion.
• Elevated liver enzymes on routine blood work (ALT, AST).
• Dark‑yellow urine and pale stools (signs of impaired bile excretion).
• Spider angiomas, palmar erythema, or enlarged spleen in advanced disease.

Because these signs are non‑specific, laboratory testing and imaging are usually required to confirm the diagnosis.

When to See a Doctor

Prompt medical evaluation is warranted if you experience any of the following:

• Persistent or worsening abdominal pain, especially in the upper right side.
• Sudden jaundice (yellowing of skin or eyes).
• Unexplained swelling in the abdomen, legs, or ankles.
• Severe, unexplained fatigue that interferes with daily activities.
• Elevated liver enzymes discovered on routine labs without a clear cause.
• History of heavy alcohol use combined with any liver‑related symptoms.

Early detection allows for lifestyle changes and medical treatment that can halt or reverse liver damage.

Diagnosis

Diagnosing fatty liver involves a combination of history, physical examination, lab tests, and imaging studies.

1. Medical History & Physical Exam

The clinician will ask about alcohol consumption, diet, weight changes, medication use, and family history of liver disease. A physical exam may reveal an enlarged liver (hepatomegaly) or signs of chronic liver disease.

2. Blood Tests

• Liver function panel – ALT, AST, alkaline phosphatase, GGT, bilirubin.
• Metabolic profile – fasting glucose, HbA1c, lipid panel.
• Viral hepatitis serologies – to rule out hepatitis B/C.
• Autoimmune markers – ANA, SMA, anti‑LKM when indicated.

3. Imaging

• Ultrasound – first‑line, non‑invasive; shows a bright liver echotexture.
• Transient elastography (FibroScan) – measures liver stiffness and fat content; helpful for assessing fibrosis.
• CT or MRI – more precise quantification but used when ultrasound is inconclusive.

4. Liver Biopsy

Only about 10‑20% of patients need a biopsy. It remains the gold standard for distinguishing simple steatosis from NASH and for staging fibrosis. The decision is based on risk factors, imaging results, and whether the diagnosis will change management.

5. Scoring Systems

Tools such as the NAFLD Fibrosis Score and the FIB‑4 index combine lab values and patient age to estimate fibrosis risk without invasive testing.

Treatment Options

Management targets the underlying cause, reduces liver fat, and prevents progression to fibrosis or cirrhosis.

1. Lifestyle Modification (First‑Line)

• Weight loss – 7‑10% body‑weight reduction improves histology in >90% of patients (Mayo Clinic). Aim for 0.5–1 kg (1–2 lb) per week.
• Dietary changes – adopt a Mediterranean‑style diet: high in vegetables, fruits, whole grains, nuts, olive oil, and fish; low in refined carbs, red meat, and sugary drinks.
• Physical activity – at least 150 minutes of moderate‑intensity aerobic exercise (e.g., brisk walking) per week, plus resistance training twice weekly.
• Alcohol abstinence – essential for AFLD and advisable for NAFLD patients.

2. Medical Therapies

• Insulin sensitizers – Pioglitazone (off‑label) improves steatosis and inflammation in NASH patients with diabetes (NIH). Use under specialist supervision.
• Vitamin E – 800 IU daily for non‑diabetic adults with biopsy‑proven NASH has shown histologic benefits (American Association for the Study of Liver Diseases, AASLD).
• Statins – safe for most patients with NAFLD; they treat dyslipidemia and may reduce cardiovascular risk.
• GLP‑1 receptor agonists – e.g., liraglutide, have emerging evidence for reducing liver fat and NASH activity.
• Newer agents – drugs such as obeticholic acid and selonsertib are under investigation; enrollment in clinical trials is an option for eligible patients.

3. Management of Comorbidities

• Control of diabetes (target HbA1c <7%).
• Treatment of hyperlipidemia (statins, omega‑3 fatty acids).
• Blood pressure control per WHO guidelines.
• Screening and treatment for obstructive sleep apnea, which worsens insulin resistance.

4. Advanced Disease

If fibrosis progresses to cirrhosis, patients may need:

• Regular surveillance for hepatocellular carcinoma (ultrasound ± AFP every 6 months).
• Management of portal hypertension (beta‑blockers, endoscopic variceal ligation).
• Liver transplantation in end‑stage disease.

Prevention Tips

Because many risk factors are modifiable, prevention focuses on healthy lifestyle choices.

• Maintain a healthy weight – BMI 18.5–24.9.
• Eat a balanced diet – prioritize whole foods, limit added sugars and saturated fats.
• Stay active – combine aerobic and resistance exercises.
• Limit alcohol – follow the CDC’s low‑risk drinking guidelines.
• Control metabolic conditions – monitor blood glucose, blood pressure, and lipids.
• Regular check‑ups – especially if you have diabetes, obesity, or a family history of liver disease.
• Review medications – talk to your physician before starting drugs known to affect the liver.

Emergency Warning Signs

Key Take‑aways

Fatty liver disease is highly prevalent but often reversible with early intervention. Understanding risk factors, recognizing subtle symptoms, and undergoing appropriate testing can prevent progression to serious liver disease. Lifestyle changes—weight loss, a nutritious diet, regular exercise, and limiting alcohol—remain the cornerstone of therapy, while several medications are available for selected patients. If you notice any warning signs listed above, do not wait: contact a healthcare professional right away.

For further reading, consult reputable sources such as the Mayo Clinic, CDC, NIH/NIDDK, and the World Health Organization.

```